Slingshot members are tracking this event:
European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo(nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
|BMY||Community voting in process|
Slingshot Insights Explained
Mar 30, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Hematological Malignancy, Checkmate -205, Relapsed Or Refractory Chl, Opdivo, Brentuximab Vedotin, Autologous Stem Cell Transplant, Hodgkin Lymphoma